Increased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity

Table 1

Clinical features of psoriatic patients from Brazil northeast.

Characteristics	All individuals ()
Age (yrs.)
Mean ± SD/range	/23–74
Gender N (%)
Male	11 (52.3)
Female	10 (47.7)
Disease duration (years)
Mean ± SD (range), all	8.1 ± 6.5 (0.5–22)
0–5 years N (%)—mean ± SD	9 (42.8)—2.1 ± 1.2
6–10 years N (%)—mean ± SD	6 (28.6)—9.1 ± 1.3
>10 years N (%)—mean ± SD	6 (28.6)—16.3 ± 4.2
PASI clinical subgroups N (%)
Mild (PASI < 10)—mean ± SD	5 (23.8)—8.8 ± 1
Moderate-severe (PASI ≥ 10)—mean ± SD	16 (76.2)—20.8 ± 5.7
Clinical comorbidities N (%)
Diabetes	3 (14.3)
Dyslipidemia	3 (14.3)
Hypertension	3 (14.3)
Treatment N (%)
Methotrexate	9 (42.9)

Considering a Gaussian distribution, clinical values were represented by mean ± SD.